The Metastatic Castrate-Resistant Prostate Cancer Patient Journey: EU5 Prescribing Preferences and Payer Strategy as Options Diversify | Physician & Payer Forum | EU5 | 2014
Three new premium-priced therapies–Xtandi (Medivation/Astellas Pharma), Provenge (Dendreon), and Xofigo (Algeta/Bayer HealthCare)–have recently been approved in Europe for prostate cancer. These agents will join existing costly therapeutics Jevtana (Sanofi) and Zytiga (Janssen), driving the metastatic castrate-resistant prostate cancer (mCRPC) market in Europe to become increasingly crowded and competitive. Therefore, as therapies seek to optimize their place in medical practice and the EU5 markets strive to tighten their healthcare belt, payers and prescribers must balance tightening budgets and evolving cost-containment policies with clinical need.
Drawing on insights from 250 surveyed medical oncologists across the EU5, 30 surveyed urologists in Germany only, and 15 interviewed payers, this report, The Metastatic Castrate-Resistant Prostate Cancer Patient Journey: EU5 Prescribing Preferences and Payer Strategy as Options Diversify, explores the evolving reimbursement and market access landscape for mCRPC, the dynamics affecting prescribing of key drugs in an increasingly cost-constrained climate, and the main challenges facing emerging therapies’ uptake in this heterogeneous market.
